PLT012 Receives FDA Fast Track Designation for Liver Cancer Treatment

The U.S. Food and Drug Administration (FDA) has granted fast track designation to PLT012, an investigational immunotherapy being studied for hepatocellular carcinoma, the most common type of liver cancer, Pilatus Biosciences Inc. announced in a news release. The designation is intended to speed the development and review of treatments for serious diseases that have limited options, and it allows for closer communication with the FDA and the potential for accelerated approval pathways.

“Receiving FDA fast track designation for PLT012 is an important milestone that reinforces the potential of our checkpoint therapy approach to transform the treatment of HCC,” said Dr. Raven Lin, co-founder and CEO of Pilatus Biosciences. “PLT012 was designed to address the metabolic adaptations that drive immune evasion in cancer. With IND clearance already secured and our phase 1 trial open for patient enrollment, this designation will help accelerate clinical development and advance towards delivering a novel therapeutic option for patients, both in HCC and other solid tumors where patients do not benefit from existing immunotherapies.”

PLT012 is a first-in-class monoclonal antibody designed to target CD36, a protein involved in how tumors suppress the immune system. By blocking CD36, researchers hope the therapy will help the immune system better recognize and attack cancer cells. A phase 1 clinical trial is already open and enrolling patients in Texas.

How PLT012 works inside the tumor microenvironment

Unlike traditional checkpoint inhibitors that target PD-1 or PD-L1, PLT012 focuses on what researchers describe as a “metabolic checkpoint.” Many tumors use altered fat metabolism to weaken immune cells in their environment. CD36 plays a key role in this process and is found on several immune cells that become exhausted in cancer, including T cells and natural killer cells.

By blocking CD36, PLT012 is designed to reduce immunosuppressive cells and reinvigorate cancer-fighting immune cells. Preclinical studies have shown activity both as a single agent and in combination with PD-1 or PD-L1 inhibitors, suggesting the drug could potentially help patients who do not respond to current immunotherapies.

Why new treatments are needed for hepatocellular carcinoma

Hepatocellular carcinoma remains difficult to treat, particularly for patients whose disease progresses after standard therapies. Although immune checkpoint inhibitors and targeted therapies have improved outcomes for some patients, many do not respond or eventually develop resistance.

Fast track designation reflects the significant unmet need in this setting. The FDA program is designed to help promising therapies move through clinical development more efficiently, which may allow patients earlier access if the treatment ultimately proves safe and effective.

PLT012 has also received orphan drug designation for liver and intrahepatic bile duct cancers, another sign that regulators recognize the need for additional treatment options in these diseases.

How the phase 1 study is designed

The ongoing phase 1 trial is evaluating the safety, tolerability, and pharmacologic profile of PLT012, along with early signs of anti-tumor activity. This type of study is the first step in determining an appropriate dose and understanding how the drug behaves in the body.

Researchers plan to expand enrollment into additional tumor types that are strongly influenced by CD36-driven metabolic changes. The study is currently recruiting patients at clinical sites in Dallas and Houston.

The trial is enrolling patients with advanced cancers, including hepatocellular carcinoma, who may have limited treatment options. Early-phase trials typically include patients whose disease has progressed after standard therapies, although specific eligibility criteria vary by study site.

Participation in a phase 1 trial primarily focuses on safety, but it can also provide access to new investigational therapies and close monitoring by a specialized research team.

Additional findings and future directions

Researchers are also exploring PLT012 in combination with existing immunotherapies, with the goal of overcoming resistance in “cold” tumors that typically do not respond well to immune-based treatments.

Although the therapy is still in early development and its effectiveness in patients has not yet been established, the fast track designation and ongoing clinical trial represent steps toward the potential to expand treatment options for people with liver cancer.

Editor's note: This article is for informational purposes only and is not a substitute for professional medical advice, as your own experience will be unique. Use this article to guide discussions with your oncologist. Content was generated with AI and reviewed by a human editor.

References

1. “PLT012 Receives FDA Fast Track Designation for Liver Cancer Treatment,” Pilatus Biosciences Inc. News release; Feb. 19, 2026.

For more news on cancer updates, research and education, don’t forget to subscribe to CURE®’s newsletters here.